서세영 조교수
#종양내과질환#암평생관리클리닉
|
학력
2013 .03 ~ 2015 .02울산대학교 의학 석사
2003 .03 ~ 2009 .02차의과학대학교 의학 학사
2003 .03 ~ 2009 .02차의과학대학교 의학 학사
경력
2020 .03 ~ 현재서울아산병원 종양내과 임상조교수
2018 .03 ~ 2020 .02서울아산병원 종양내과 임상전임강사(전임의, 펠로우)
2017 .03 ~ 2018 .02서울아산병원 종양내과 촉탁임상전임강사
2017 .03 ~ 2018 .02서울아산병원 종양내과 촉탁임상전임강사
2015 .03 ~ 2017 .02서울아산병원 종양내과 임상강사(전임의, 펠로우)
2011 .03 ~ 2015 .02서울아산병원 내과 전공의(레지던트)
2009 .02 ~ 2010 .02서울아산병원 수련의(인턴)
2018 .03 ~ 2020 .02서울아산병원 종양내과 임상전임강사(전임의, 펠로우)
2017 .03 ~ 2018 .02서울아산병원 종양내과 촉탁임상전임강사
2017 .03 ~ 2018 .02서울아산병원 종양내과 촉탁임상전임강사
2015 .03 ~ 2017 .02서울아산병원 종양내과 임상강사(전임의, 펠로우)
2011 .03 ~ 2015 .02서울아산병원 내과 전공의(레지던트)
2009 .02 ~ 2010 .02서울아산병원 수련의(인턴)
논문
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis.
The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non?small cell lung cancer
Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Prognostic signifiance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric
Castleman's disease: a single medical center experience
Multiple myeloma in a patient with acromegaly.
The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis.
The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non?small cell lung cancer
Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Prognostic signifiance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric
Castleman's disease: a single medical center experience
Multiple myeloma in a patient with acromegaly.
The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
저서
저서 내용이 없습니다.
보도자료
보도자료 내용이 없습니다.
포스팅
Comparison of Oxaliplatin-Related Spleen Enlargement in Patient with Gastric Cancer who Received S-1 versus Capecitabine as a Combination Partner of Oxaliplatin
The prognostic impact of FGFR2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced gastric cancers
The prognostic impact of FGFR2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced gastric cancers
영상자료
영상자료 내용이 없습니다.
발표자료
발표자료 내용이 없습니다.